Replimune Group, Inc. (REPL) Dividend History

Company News

• Metastatic Colorectal Cancer Clinical Trial Pipeline Accelerates as 150+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight

  The metastatic colorectal cancer pipeline is rapidly expanding, with over 150 pharmaceutical companies developing 180+ pipeline drugs. Novel therapies, including small molecules, antibodies, and tumor microenvironment modulators, are gaining traction and could reshape the treatment landscape.

  GlobeNewswire Inc.

  Featured Companies: EXEL LPTX
• Replimune Announces Pricing of Upsized Public Offering

  Replimune Group, Inc. announced the pricing of its public offering of 6,923,000 shares of common stock and 3,846,184 pre-funded warrants, with expected gross proceeds of approximately $140 million.

  GlobeNewswire Inc.
• Non-melanoma Skin Cancer is Predicted to Exhibit Remarkable Growth During the Study Period (2020–2034) | DelveInsight

  The non-melanoma skin cancer market is expected to grow significantly due to the rising incidence of the disease and the development of new therapies. Key players like Sirnaomics, AiViva BioPharma, and Replimune are working on innovative drugs for NMSC.

  GlobeNewswire Inc.
• Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

  Replimune Group, a clinical-stage biotechnology company, announced the grant of inducement equity awards to 9 newly hired non-executive employees as a material inducement to commencing their employment.

  GlobeNewswire Inc.
• Replimune Presents Primary Analysis Data from IGNYTE Clinical Trial of RP1 Combined with Nivolumab in Anti-PD1 Failed Melanoma at European Society for Medical Oncology (ESMO) Congress 2024

  Replimune presented positive data from the primary analysis of the IGNYTE clinical trial, showing clinically meaningful and durable systemic anti-tumor activity of RP1 combined with nivolumab in anti-PD1 failed melanoma patients.

  GlobeNewswire Inc.